Bartoli v. Novartis Pharmaceuticals Corporation
John Bartoli |
Margaret Cartelli and Novartis Pharmaceuticals Corporation |
3:2013cv00724 |
March 19, 2013 |
US District Court for the Middle District of Pennsylvania |
Scranton Office |
Outside State |
Malachy E Mannion |
Personal Inj. Prod. Liability |
28 U.S.C. ยง 1332 Diversity-Personal Injury |
Both |
Available Case Documents
The following documents for this case are available for you to view or download:
Document Text |
---|
Filing 214 ORDER (memorandum filed previously as separate docket entry)Defendants motion to exclude the testimony of Dr. Skubitz, (Doc. 183), is GRANTED IN PART AND DENIED IN PART. Defendants motion is GRANTED as to Dr. Skubitzs observations regarding the incid ence of ONJ in his own patients after he implemented a reduced dosing regimen, and DENIED as to testimony regarding the benefits of alternative dosing, the benefits of pre-therapy dental screening, and incidence of ONJ;(2)Defendants motion to exclude the testimony of Dr. Marx, (Doc. 185), is GRANTED IN PART AND DENIED IN PART. Defendants motion is GRANTED as to testimony regarding whether NPC engaged in bad faith conduct, and the adequacy of the clinical trials. Defendants motion is DENIED as to opinions on preventative dental screenings, the opinion that some of the clinical trial patients had ONJ, general causation opinions based on adverse event reports, and opinion of the biological mechanism by which BPs allegedly cause ONJ;(3)Defendan ts motion to exclude the testimony of Dr. Suzanne Parisian, (Doc. 187), is GRANTED IN PART AND DENIED IN PART. Defendants motion is GRANTED as to testimony of NPCs intent, pharmaceutical industry ethical standards, ghostwriting, and undisclosed compa ny funding of publications, and causation. Defendants motion is DENIED as to opinions regarding regulatory compliance and the reasonableness of NPC's conduct in its interactions with the FDA and compliance with FDA regulations;(4)Defendants moti on to exclude the testimony of Prof. Wayne Ray, (Doc. 189), is GRANTED IN PART AND DENIED IN PART. Defendants motion is GRANTED as to the Table 6 meta-analysis and the use of the word rare in relation to the incidence rate. Defendants motion is DENIE D as to the Table 5 meta-analysis, the biological plausibility that BPs cause ONJ, the opinion that a causation determination could have been reached in 2003, and an opinion that the incidence rate of ONJ in BP users is 5%, and;(5)Defendants mot ion to exclude the testimony of Dr. James Vogel, (Doc. 191), is GRANTED IN PART AND DENIED IN PART. Defendants motion is GRANTED to the extent that Dr. Vogel may not opine as to the intent or motive of NPC. Defendants motion is DENIED as to testimony regarding pre-dental screenings, incidence rate of ONJ in patients, alternative BP dosing regimens, and the biological mechanism by which BPs affect the jaw bone.Signed by Honorable Malachy E Mannion on 4/17/14. (bs) |
Filing 150 MEMORANDUM Signed by Chief Judge Todd J. Campbell on 8/13/09 [USDC MDTN Doc 2767] (ts) |
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Pennsylvania Middle District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.